STOCK TITAN

Adicet Bio, Inc. - $ACET STOCK NEWS

Welcome to our dedicated page for Adicet Bio news (Ticker: $ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adicet Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adicet Bio's position in the market.

Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) will present at the 2023 Jefferies London Healthcare Conference on November 14, 2023. The presentation will be available via live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
conferences
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has announced the acceptance of a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation will focus on the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. The presentation will be given by Dr. Monica Moreno on December 10, 2023, from 6:00 - 8:00 p.m. PDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.85%
Tags
none
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has granted an inducement award to a new employee, consisting of 5,000 non-qualified stock options. The exercise price is $1.32 per share, with vesting scheduled over a four-year period. The award was granted outside of Adicet's stockholder-approved equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
Rhea-AI Summary
Adicet Bio presents promising approach for prostate cancer with their Allogeneic Gamma Delta T Cell Platform at upcoming conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary
Adicet Bio grants inducement awards to new hires, offering non-qualified stock options to purchase 32,200 shares at $1.37 per share. Vesting occurs over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Adicet Bio announces acceptance of three abstracts for poster presentation at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences
Rhea-AI Summary
Adicet Bio grants inducement awards to new hires
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
conferences
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) Grants Inducement Awards to New Hires: Adicet Bio, a biotechnology company, announced the granting of inducement awards to four new hires in July 2023. The awards consist of non-qualified stock options to purchase 73,400 shares of Adicet’s common stock at an exercise price of $2.67 per share. These awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to the Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
none
Adicet Bio, Inc.

Nasdaq:ACET

ACET Rankings

ACET Stock Data

131.47M
49.05M
1.42%
67.94%
9.36%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
BOSTON

About ACET

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v